NPY1R and neurodegenerative disease: The inclusion of these models will allow us to directly assess the therapeutic improvements offered by the NPY1R agonist and ketamine combination in a context that closely mirrors the pathological state of neurodegenerative diseases, thereby enhancing the translational value of our findings.